ACLX
Arcellx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.71B
P/E Ratio
—
EPS
$-4.07
Beta
0.25
52W High
$114.94
52W Low
$47.86
50-Day MA
$95.02
200-Day MA
$79.52
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
61.73
PEG Ratio
—
About Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, is engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | $22.29M |
| Gross Profit (TTM) | $-135.32M |
| EBITDA | $-246.40M |
| Operating Margin | -3850.00% |
| Return on Equity | -53.40% |
| Return on Assets | -24.00% |
| Revenue/Share (TTM) | $0.40 |
| Book Value | $6.95 |
| Price-to-Book | 16.68 |
| Price-to-Sales (TTM) | 301.03 |
| EV/Revenue | 283.3 |
| EV/EBITDA | -6.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -89.20% |
| Shares Outstanding | $58.48M |
| Float | $42.25M |
| % Insiders | 12.85% |
| % Institutions | 89.89% |
Analyst Ratings
Consensus ($111.07 target)
18
HoldData last updated: 4/7/2026